Cervical epidural venous engorgement after cerebrospinal fluid shunting: clinical-radiological correlation and systematic review.

Neurosurg RevSep 17, 2026 (epub)
Case ReportNeurologyNeurosurgeryRadiology (Diagnostic)Open access

Gianluca Scalia, Rosalba Pitoia, Roberta Finocchiaro et al.

✦ AI-curated · Sources linked

Case in brief

A 73-year-old patient developed acute cervical epidural venous engorgement and hematoma following ventriculoperitoneal shunting for normal pressure hydrocephalus. The patient presented with progressive cervical myelopathy, but without the typical symptoms of intracranial hypotension. After valve reprogramming to correct overdrainage, the patient's condition improved completely.

Diagnostic / clinical pearl

Cervical epidural venous engorgement can occur after CSF shunting and may present with myelopathy, often without typical signs of intracranial hypotension. Early recognition and management of CSF dynamics are crucial.

Source

PubMed · PMID 42753006Free full text on PubMed Central

Published in Neurosurg Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.